Month: March 2025

Varonis Acquires Cyral to Reinvent Database Activity Monitoring

Written by Customer Service on March 17, 2025. Posted in Mergers And Acquisitions.

Strategic DAM acquisition accelerates Varonis’ mission to deliver AI-powered data security for all enterprise data, everywhere MIAMI, March 17, 2025 (GLOBE NEWSWIRE) — Varonis Systems, Inc. (Nasdaq: VRNS), the data security leader, today announced the acquisition of the next-generation database activity monitoring (DAM) provider Cyral. Cyral’s innovative approach to DAM uses agentless and stateless interception technology that deploys quickly and overcomes the challenges legacy vendors face in preventing data breaches and ensuring compliance. “By combining Cyral’s cloud-native DAM with Varonis’ robust and growing database security capabilities, customers can begin to upgrade their costly legacy solutions, shattering the silos that have traditionally separated structured and unstructured data security,” said Varonis CEO, President,...

Springbig Announces Acquisition of VICE CRM and Appointment of Jaret Christopher as Chief Executive Officer

Written by Customer Service on March 17, 2025. Posted in Mergers And Acquisitions.

BOCA RATON, Fla., March 17, 2025 (GLOBE NEWSWIRE) — SpringBig Holdings, Inc. (“Springbig” or the “Company”) (OTCQX: SBIG), a leading provider of SaaS-based marketing solutions, consumer mobile app experiences, and omnichannel loyalty programs, today announced the acquisition of VICE CRM, an AI-enabled performance marketing platform designed to optimize ROI for consumer marketing campaigns in highly regulated industries. In addition, the Company has appointed VICE CRM founder, Jaret Christopher, as Chief Executive Officer effective April 1, 2025. Jaret Christopher brings extensive leadership experience in SaaS-based businesses and knowledge of the cannabis market. Most recently, Jaret was General Manager and Vice President, CRM Software at WM Technologies, Inc., a position he held until last year following the sale of Sprout, a...

XOMA Royalty Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Business Achievements

Written by Customer Service on March 17, 2025. Posted in Earnings Releases And Operating Results.

Doubled the royalty and milestone portfolio to over 120 royalty assets with significant milestone potential through five transactions in 2024 Completed two whole company acquisitions to unlock shareholder value Day One’s OJEMDA™ (tovorafenib) and Zevra’s MIPLYFFA™ (arimoclomol) each received FDA approval Cash receipts totaled $4.0 million in the fourth quarter and $46.3 million for the full year 2024 EMERYVILLE, Calif., March 17, 2025 (GLOBE NEWSWIRE) — XOMA Royalty Corporation (NASDAQ: XOMA), the biotech royalty aggregator, reported its fourth quarter and full year 2024 financial results and highlighted recent activities. “Our balanced approach to building the scale of XOMA Royalty’s portfolio by selectively acquiring royalty economics across the lifecycle of drug development is beginning to bear fruit,” stated...

Dillard’s, Inc. Amends and Extends Revolving Credit Facility

Written by Customer Service on March 17, 2025. Posted in Public Companies.

LITTLE ROCK, Ark., March 17, 2025 (GLOBE NEWSWIRE) — Dillard’s, Inc. (DDS-NYSE) (“Dillard’s” or “the Company”) announced that it has amended and extended its $800 million senior secured revolving credit facility consistent with the Company’s liquidity needs. A $200 million expansion option remains in place. The new maturity date is March 12, 2030. The credit facility is available to the Company for general corporate purposes including, among other uses, working capital financing, the issuance of letters of credit, capital expenditures and, subject to certain restrictions, the repayment of existing indebtedness and share repurchases. There are no financial covenant requirements under the amended credit agreement provided availability exceeds $80 million and no specified event of default has occurred or is continuing. The credit...

Natural Gas Services Group, Inc. Reports Fourth Quarter and Year-End 2024 Financial and Operating Results; Provides 2025 Guidance

Written by Customer Service on March 17, 2025. Posted in Earnings Releases And Operating Results.

Midland, Texas, March 17, 2025 (GLOBE NEWSWIRE) — Natural Gas Services Group, Inc. (“NGS” or the “Company”) (NYSE:NGS), a leading provider of natural gas compression equipment, technology, and services to the energy industry, today announced financial results for the three months and year-ended December 31, 2024. The Company also provided guidance for its full year 2025, anticipating significant top- and bottom-line growth with strong momentum moving into 2026. Fourth Quarter and Full Year 2024 HighlightsRental revenue of $38.2 million for the fourth quarter and $144.2 million for the full year 2024, representing increases of 21% and 36%, respectively, compared to the prior year comparable periods.Net income of $2.9 million or $0.23 per diluted share for the fourth quarter and $17.2 million or $1.37 per diluted share for the...

Akoya Reports Fourth Quarter of 2024 and Full Year Financial Results

Written by Customer Service on March 17, 2025. Posted in Mergers And Acquisitions.

MARLBOROUGH, Mass., March 17, 2025 (GLOBE NEWSWIRE) — Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced its financial results for the fourth quarter and full year ending December 31, 2024. “Akoya navigated a challenging 2024 in the life science tools market, which was constrained by subdued capital equipment purchases, by successfully strengthening gross margins, reducing operating expenses and advancing our companion diagnostics programs throughout the year. We remain optimistic about the long-term growth outlook of Akoya’s leading spatial biology solutions,” said Brian McKelligon, CEO of Akoya. “In 2024, Akoya achieved multiple milestones, including expanding our market-leading installed base to 1,330 instruments, launching our Manufacturing Center of Excellence...

Enzo Biochem Reports Second Quarter Fiscal Year 2025 Results

Written by Customer Service on March 17, 2025. Posted in Earnings Releases And Operating Results.

FARMINGDALE, N.Y., March 17, 2025 (GLOBE NEWSWIRE) — Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”) today announced financial results for the fiscal second quarter ended January 31, 2025, with sequential quarter improvement in revenue, gross margin and operating profit / loss. Financial HighlightsThe Company’s second-quarter gross margin percentage of 52% increased sequentially from 37% during Q1 2025 and increased from 49% during the second quarter of the prior year. These improvements were driven by change in revenues, cost efficiency actions completed, and mix of products sold. The Enzo Life Sciences Products segment, which excludes discontinued operations and Corporate overhead, achieved a $0.5 million operating profit during Q2 FY25, a $2M sequential improvement compared to a $1.5 operating loss during Q1 FY25,...

Interparfums, Inc. Announces Acquisition of the Goutal Brand

Written by Customer Service on March 17, 2025. Posted in Mergers And Acquisitions.

NEW YORK, March 17, 2025 (GLOBE NEWSWIRE) — Interparfums, Inc. (NASDAQ GS: IPAR) (“Interparfums” or the “Company”) today announced that its subsidiary, Interparfums SA, has acquired all worldwide intellectual property rights relating to Maison Goutal held by Amorepacific Europe. Amorepacific Europe will continue to operate the Goutal Brand under a license agreement for a set duration. Interparfums SA will develop the brand from 2026 onwards, together with its licensee. Created by Annick Goutal in 1981, the eponymous brand positioned itself from the start in the exclusive high-end segment with the launch of the L’Eau d’Hadrien line and the opening of a first boutique on Rue de Bellechasse in Paris. Known for refined and poetic creations, Goutal successively developed a wide range of perfume, bath and home fragrance lines, marketed...

Gyre Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Written by Customer Service on March 17, 2025. Posted in Earnings Releases And Operating Results.

Data from pivotal Phase 3 trial in CHB-associated liver fibrosis expected in Q2 2025 Commercial launch in the PRC of generic nintedanib for the treatment of IPF and avatrombopag maleate tablets for the treatment of CLD-associated thrombocytopenia expected in 2025 Initiation of U.S. Phase 2 trial of F351 in MASH-associated liver fibrosis expected in 2025 Full year 2025 total revenue guidance of $118 to $128 million SAN DIEGO, March 17, 2025 (GLOBE NEWSWIRE) — Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), a self-sustainable, commercial-stage biotechnology company with clinical development programs focusing on organ fibrosis, today announced financial results for the fourth quarter and full year ended December 31, 2024 and provided a business update. “2025 is shaping up to be a pivotal year for Gyre across both our commercial-stage...

Baltic Horizon Fund completed the sale of Meraki Business Home in Vilnius, Lithuania

Written by Customer Service on March 17, 2025. Posted in Public Companies.

The owner of Meraki Business Home in Vilnius, BH Meraki UAB, an SPV of Baltic Horizon Fund, closed a transaction at the end of last week, in accordance with which Groa Real Estate Opportunity Fund UAB, a fund managed by Groa Capital purchased Meraki Business Home in Vilnius, Lithuania. The sales price of the asset was approximately EUR 16 million. The proceeds of the transaction will be used to redeem EUR 3 million of Baltic Horizon Fund bonds and repay the loan from Bigbank. Baltic Horizon Fund informed the investors about the signing of the sale and purchase agreement via a stock exchange announcement published on 7 March 2025: https://view.news.eu.nasdaq.com/view?id=b44b29e9e4e39243051682af0fe3b84f5&lang=en&src=listed. For additional information, please contact: Tarmo Karotam Baltic Horizon Fund manager E-mail tarmo.karotam@nh-cap.com...

Month: March 2025

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals